Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Operating Margin: 2009-2025

Historic Operating Margin for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -8,613.38%.

  • Cytokinetics' Operating Margin rose 2179721.00% to -8,613.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -671.79%, marking a year-over-year increase of 1562600.00%. This contributed to the annual value of -3,574.99% for FY2024, which is 301472.00% up from last year.
  • According to the latest figures from Q3 2025, Cytokinetics' Operating Margin is -8,613.38%, which was down 5,057.63% from -167.00% recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Operating Margin peaked at -12.22% during Q2 2022, and registered a low of -52,277.91% during Q2 2024.
  • For the 3-year period, Cytokinetics' Operating Margin averaged around -15,828.32%, with its median value being -9,856.30% (2025).
  • Per our database at Business Quant, Cytokinetics' Operating Margin crashed by 3,820,075bps in 2024 and then skyrocketed by 5,211,091bps in 2025.
  • Quarterly analysis of 5 years shows Cytokinetics' Operating Margin stood at -39.57% in 2021, then slumped by 645,149bps to -6,491.06% in 2022, then slumped by 112,964bps to -7,620.69% in 2023, then skyrocketed by 669,376bps to -926.93% in 2024, then soared by 2,179,721bps to -8,613.38% in 2025.
  • Its Operating Margin stands at -8,613.38% for Q3 2025, versus -167.00% for Q2 2025 and -9,856.30% for Q1 2025.